Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer

Status unconfirmed

Conditions studied: Colorectal Cancer

In brief

The goal of this laboratory research is to look for genes that can predict which patients will achieve a complete disappearance of their colorectal cancer after treatment like chemotherapy, radiation, or other therapy. This is an investigational study. Up to 350 patients will take part in this study. All will be enrolled at MD Anderson.

Key facts

Study ID

NCT02877056

Run by

M.D. Anderson Cancer Center

People needed

250

Starts

2005-08-01

Expected to finish

2023-08-01

Last updated by the study team

2019-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with colorectal adenocarcinoma (diagnosis based on either MDACC or outside records)
• Patients scheduled to undergo neoadjuvant therapy per MDACC care team.
• Patients over 18 years of age.
• Patients with distant organ findings deemed to be indeterminate or metastatic will be enrolled at the surgeon's discretion.
• Patients who have been deemed medically safe to undergo endoscopic biopsy by the physician performing the procedure.
• Patients who would have typically undergone preoperative therapy followed by surgery but for specific reasons at the discretion of the treating physician underwent surgery without preoperative therapy may be enrolled at the surgeons' discretion.

You may not qualify if…

• N/A

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.